i wanted to know what rival companies were doing in nash and i found akero therapeutics .fierce biotech did a marvelous piece on akero so i looked at it.
then i found avisol capital partners writing some nice things about akero.
i do believe our 350mg nash is ahead of akero therapeutics all because leronlimab is a superior molecule to their efruxifermin. what you need to know is akero was able to raise a lot of money off their nash results so our results should help us too.this seeking alpha just another hit piece most likely to benefit the shorts.
https://www.fiercebiotech.com/biotech/analyst...best-class